|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Helsinki University Funded by academic grant from Merck & Co, Inc. |
|---|---|
| Information provided by: | Helsinki University |
| ClinicalTrials.gov Identifier: | NCT00559546 |
Purpose
The purpose of the study is to find out if montelukast can be used to treat the various symptoms of allergic syndrome.
| Condition | Intervention | Phase |
|---|---|---|
|
Seasonal Allergic Rhinitis Allergic Conjunctivitis Atopic Eczema Asthma |
Drug: montelukast |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver), Placebo Control, Crossover Assignment, Efficacy Study |
| Official Title: | Montelukast as a Controller of Atopic Syndrome |
| Enrollment: | 61 |
| Study Start Date: | March 2007 |
| Study Completion Date: | July 2007 |
| Arms | Assigned Interventions |
|---|---|
|
1: Active Comparator
3 weeks of Montelukast and 3 weeks of placebo treatment
|
Drug: montelukast
10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
|
|
2: Active Comparator
3 weeks of placebo and 3 weeks of montelukast treatment
|
Drug: montelukast
10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
|
Eligibility| Ages Eligible for Study: | 18 Years to 40 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Allergic symptoms in both upper airways (allergic rhinitis) and lower airways (asthma-like symptoms or diagnosed asthma) and at least one of the following:
Exclusion Criteria:
Contacts and Locations| Finland | |
| Skin and Allergy Hospital, Helsinki University Hospital | |
| Helsinki, Finland, 00029 HUS | |
| Principal Investigator: | Tari Haahtela, Professor | Skin and Allergy Hospital, Helsinki University Hospital |
More Information
| Study ID Numbers: | HUS7/E5/07 |
| Study First Received: | November 15, 2007 |
| Last Updated: | November 15, 2007 |
| ClinicalTrials.gov Identifier: | NCT00559546 History of Changes |
| Health Authority: | Finland: National Agency for Medicines |
|
Dermatitis, Atopic Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Rhinitis Eczema Hormones Leukotriene Antagonists Hypersensitivity Respiratory Tract Diseases Respiratory Tract Infections Skin Diseases, Eczematous Skin Diseases, Genetic Dermatitis |
Otorhinolaryngologic Diseases Conjunctivitis, Allergic Skin Diseases Eye Diseases Anti-Asthmatic Agents Asthma Conjunctivitis Conjunctival Diseases Montelukast Genetic Diseases, Inborn Rhinitis, Allergic, Seasonal Hypersensitivity, Immediate Respiratory Hypersensitivity |
|
Respiratory System Agents Dermatitis, Atopic Hormone Antagonists Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Rhinitis Leukotriene Antagonists Hypersensitivity Respiratory Tract Diseases Respiratory Tract Infections Therapeutic Uses Skin Diseases, Eczematous Skin Diseases, Genetic Dermatitis Otorhinolaryngologic Diseases |
Immune System Diseases Conjunctivitis, Allergic Skin Diseases Eye Diseases Anti-Asthmatic Agents Conjunctivitis Pharmacologic Actions Conjunctival Diseases Nose Diseases Montelukast Genetic Diseases, Inborn Rhinitis, Allergic, Seasonal Hypersensitivity, Immediate Respiratory Hypersensitivity |
